Alzheimer Disease Clinical Trial
— EARHLIOfficial title:
Early Age-Related Hearing Loss Investigation (EARHLI): A Randomized Controlled Trial to Assess the Mechanisms Linking Early Age-Related Hearing Loss and Alzheimer's Disease and Related Dementias
Early Age-Related Hearing Loss Investigation (EARHLI) is a single site study that will randomize late middle age adults to either a hearing intervention (including hearing aids) or a health education intervention. Participants will be followed for 1 year. This study will provide information on reducing cognitive decline in those at risk for Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD).
Status | Recruiting |
Enrollment | 150 |
Est. completion date | February 1, 2028 |
Est. primary completion date | February 1, 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 55 Years to 75 Years |
Eligibility | Inclusion Criteria: - Age 55-75 years of age - Adult-onset hearing loss of approximately mild to moderate in severity (4-frequency 0.5, 1, 2, 4 kHz pure tone average 20 dB to 55 dB HL in better hearing ear) - Aidable hearing loss, defined by word recognition score in quiet = 60% in better hearing ear - Amnestic mild cognitive impairment (MCI) defined by Mini-Mental State Exam (MMSE2) score >23, Clinical Dementia Rating (CDR) global score equivalent = 0.5, and ADNI3 criteria of Logical Memory II score of =6 if 0-7 years of education, =9 if 8-15 years, and =11 if =16 years - Availability of a study partner (informant) for the administration of the cognitive screen and the ADCS-Activities of Daily Living-Prevention Instrument (ADCS-ADL-PI) - Community-dwelling - Fluent in English or Spanish - Availability of participant in area for study duration Exclusion Criteria: - Self-reported congenital hearing loss, known genetic mutation-related hearing loss, or hearing loss onset before middle age (<45 years old) - Prior dementia diagnosis - Reported disability in = 2 activities of daily living (ADLs) - Current or previous consistent hearing aid user (such as utilization of hearing aids within the past 6 months beyond brief trials) - Unwillingness to wear hearing aids regularly (=8 hours/day) - Medical contraindications to the use of hearing aids (e.g., actively draining ear) - Corrected vision impairment (worse than 20/63 on MNRead Acuity Chart in worse eye) - Untreatable conductive hearing loss with air-bone gap > 15 dB in two or more contiguous octave frequencies in both ears |
Country | Name | City | State |
---|---|---|---|
United States | Columbia University Medical Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Columbia University | Johns Hopkins University, National Institute on Aging (NIA), University of Pittsburgh, University of South Florida, University of Washington |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Hearing Handicap Index for Adults and the Elderly-Short (HHIS) Score | This test evaluates self perceived hearing handicap. Score ranges from 0 - 48, a higher score indicates higher perception of problems secondary to hearing loss. | Week 0, Week 28, Week 52 | |
Other | Hearing Handicap Index-Short-Significant Other (HHIO) Score | This test evaluates hearing handicap perceived by subjects significant other. Score ranges from 0 - 48, a higher score indicates higher perception of problems secondary to hearing loss. | Week 0, Week 28, Week 52 | |
Other | Speech, Spatial and Qualities of Hearing Scale (SSQ12) Score | This test evaluates a range of hearing disabilities across several domains. Scored from 0 - 120, a higher score indicates better hearing. | Week 0, Week 28, Week 52 | |
Other | Vanderbilt Fatigue Scale (VFS) Score | This test evaluates listening-related fatigue in individuals with hearing loss and other communication-based difficulties. Scored from 0 - 40, a higher score indicates more symptoms of fatigue related to hearing loss. | Week 0, Week 28, Week 52 | |
Other | Pittsburgh Fatigability Scale (PFS) Score | This test evaluates self-report whole-body physical and mental tiredness related to activities of fixed intensity and duration in adults. Scored from 0 - 50, a higher score indicates more symptoms of fatigue. | Week 0, Week 28, Week 52 | |
Other | Quick Inventory of Depressive Symptoms (QIDS) Score | Assesses the 9 criterion domains used to diagnose a depressive disorder. Scored 0 - 27 This is the Depression/Depressive Symptom Measure #1: Higher score indicates the presence of more depressive symptoms. | Week 0, Week 28, Week 52 | |
Other | CESD-12 Depression (CES) Score | This is the Depression/Depressive Symptom Measure # 2: Evaluates symptoms of depression. Possible range of scores is 0 -26, with the higher scores indicating the presence of more symptomatology | Week 0, Week 28, Week 52 | |
Other | RAND Short-Form 36 (SF36) | This is a general measure of quality of life | Week 0, Week 28, Week 52 | |
Primary | Free and Cued Selective Reminding Test (FC-SRT) Score | This is the Cognitive Performance Test # 1 ADCS-PACC 1: Evaluates Episodic Memory. Scoring from 0 - 48 and a higher score translates into a preserved function of the episodic memory. | Week 0, Week 28, Week 52 | |
Primary | Delayed Recall Log Memory IIa, (DRLM) Score | This is the Cognitive Performance Test # 2 ADCS-PACC 2: Evaluates Episodic Memory. Scoring from 0 - 25 and a higher score translates into a preserved function of the episodic memory. | Week 0, Week 28, Week 52 | |
Primary | Digit Symbol Substitution Test, (DSST) Score | This it the Cognitive Performance test # 3 ADCS-PACC 3: Evaluates speed of processing. Scoring from 0 - 91 and a higher score relates to better performance and speed of processing. | Week 0, Week 28, Week 52 | |
Primary | Mini-Mental State Examination 2, (MMSE-2) Score | This is the Cognitive Performance test # 4 ADCS-PACC 4: Evaluates Global Cognition. Scoring from 0 - 30 and a higher score relates to preserved Global Cognition. | Week 0, Week 28, Week 52 | |
Primary | Trail Making Test Part B, (TMTB) Score | This is the Cognitive Performance test # 5 Evaluates Episodic Memory. Scored in terms of the time, in seconds, required to complete the trail. 300 seconds = maximum amount of time. The less seconds it takes to complete the trail, the better performance/ episodic memory. | Week 0, Week 28, Week 52 | |
Primary | Activities of Daily Living for Mild Cognitive Impairment, (ADCS-ADLPI) Score | This is the Cognitive Performance test # 6: Evaluates the ability of patients to perform Activities of Daily Living. Section a. Scored from 0 - 45: Items 1 to 15. Higher score for each activity equals better performance. Section b. Scored from 0 - 5. Item 16 to 20. Higher score equals better performance | Week 0, Week 28, Week 52 | |
Primary | Social Activity Frequency | This is the Social Engagement and Related Socialization test # 1: Evaluates frequency of social activity participation. Participants are asked on a 5-point scale how often during the past 6 months they engaged in 6 common activities involving socialization. A composite score is created | Week 0, Week 28, Week 52 | |
Primary | Ability to Participate in Social Roles and Activities (APSR) Score | This is the Social Engagement and Related Socialization test # 2: Evaluates Social Activity Participation. Scored from 8 - 40 a higher score translates into higher levels of social participation. | Week 0, Week 28, Week 52 | |
Primary | Community Integration Measure (CIM) Score | This is the Social Engagement and Related Socialization test # 3: Evaluates Community Integration/Participation. Scored from 10 - 50. Higher scores indicate higher levels of community integration and participation. | Week 0, Week 28, Week 52 | |
Primary | Cohens Social Network Index (SNI) Score | This is the Social Engagement and Related Socialization test # 4: Evaluates Social Relationships. Scored from 1 - 12. Higher score indicates a larger number of social roles in which the respondent has regular contact. | Week 0, Week 28, Week 52 | |
Primary | University of California Loneliness Scale (ULS) Score | This is the Social Engagement and Related Socialization test # 5: Evaluates Individuals perception of loneliness. The total score ranges from 20 - 80. Higher scores indicate higher loneliness. | Week 0, Week 28, Week 52 | |
Primary | Brain MRI Measures | Approximately 50% of all participants (random selection) will have a functional brain MRI. | Week 0, Week 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |